Woodline Partners LP Buys 680,148 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Woodline Partners LP boosted its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 111.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,288,401 shares of the specialty pharmaceutical company’s stock after acquiring an additional 680,148 shares during the period. Woodline Partners LP owned approximately 2.61% of KalVista Pharmaceuticals worth $10,913,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its position in shares of KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 1,319 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 5,502 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in KalVista Pharmaceuticals by 14.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 696,037 shares of the specialty pharmaceutical company’s stock worth $5,895,000 after purchasing an additional 89,001 shares during the period. Wellington Management Group LLP boosted its stake in KalVista Pharmaceuticals by 4.2% during the fourth quarter. Wellington Management Group LLP now owns 122,863 shares of the specialty pharmaceutical company’s stock worth $1,041,000 after buying an additional 4,940 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in KalVista Pharmaceuticals by 29.1% during the fourth quarter. Wells Fargo & Company MN now owns 20,165 shares of the specialty pharmaceutical company’s stock worth $171,000 after buying an additional 4,543 shares in the last quarter.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 2,776 shares of the stock in a transaction on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the sale, the insider now owns 106,611 shares in the company, valued at approximately $1,262,274.24. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 3,808 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $11.84, for a total value of $45,086.72. Following the completion of the transaction, the chief executive officer now directly owns 293,367 shares of the company’s stock, valued at $3,473,465.28. This represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 15,647 shares of company stock worth $181,770 over the last ninety days. Corporate insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Stock Performance

KALV opened at $11.42 on Friday. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50. The firm has a market cap of $567.76 million, a price-to-earnings ratio of -3.14 and a beta of 0.05. The firm’s 50-day simple moving average is $11.97 and its 200-day simple moving average is $10.45.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on KALV shares. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an “outperform” rating and a $19.00 price objective for the company. Jones Trading reissued a “buy” rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $24.83.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).